



## **Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)**

SAN CARLOS, Calif., May 30, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Nektar Therapeutics (Nasdaq: NKTR) will host a meeting and Webcast on Monday, June 2, 2008 at 6:30 PM Central Time to discuss the company's lead oncology program, NKTR-102 (PEG-irinotecan). The Webcast will include a presentation by featured speaker Dr. Daniel D. Von Hoff, M.D., F.A.C.P, the lead investigator for the NKTR-102 Phase 1 trial. Dr. Von Hoff is Physician-in-Chief and Senior Investigator at the Translational Genomics Research Institute (TGen), Chief Scientific Officer for the Scottsdale Clinical Research Institute at Scottsdale Healthcare, and Chief Scientific Officer of US Oncology.

A live audio-only Webcast of this presentation can be accessed beginning at 6:30 PM Central Time on June 2, 2008 through a link posted on the Nektar website: <http://www.nektar.com/wt/page/asco>. A replay will also be accessible through the same link through June 15, 2008.

To attend this event in person, please RSVP no later than Sunday, June 1, 2008 to Vanessa Rivas: [vrivas@nektar.com](mailto:vrivas@nektar.com).

Time: 6:00 - 6:30 PM (Central Time) -- Registration  
6:30 PM (Central Time) -- Webcast presentation

Location: Fulton's on the River  
Riverfront Room and Veranda  
315 N. LaSalle Street  
Chicago, IL 60610

### About Nektar

Nektar Therapeutics is a biopharmaceutical company that develops and enables differentiated therapeutics with its industry-leading PEGylation and pulmonary drug development platforms. Nektar PEGylation technology has enabled eight approved products for partners, which include leading pharmaceutical and biotechnology companies. Nektar also develops its own products by applying its PEGylation and pulmonary technology platforms to existing medicines with the objective to enhance performance, such as improving efficacy, safety and compliance.

Contact: Jennifer Ruddock, +1-650-283-6253, [jruddock@nektar.com](mailto:jruddock@nektar.com)

SOURCE Nektar Therapeutics

<http://www.nektar.com>

Copyright (C) 2008 PR Newswire. All rights reserved

News Provided by COMTEX